Last reviewed · How we verify

AZD8835 in combination with fulvestrant — Competitive Intelligence Brief

AZD8835 in combination with fulvestrant (AZD8835 in combination with fulvestrant) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Androgen receptor inhibitor. Area: Oncology.

phase 1 Androgen receptor inhibitor Androgen receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AZD8835 in combination with fulvestrant (AZD8835 in combination with fulvestrant) — AstraZeneca. AZD8835 is a selective and potent inhibitor of the androgen receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AZD8835 in combination with fulvestrant TARGET AZD8835 in combination with fulvestrant AstraZeneca phase 1 Androgen receptor inhibitor Androgen receptor
Talazoparib with enzalutamide talazoparib-with-enzalutamide Pfizer marketed PARP inhibitor and androgen receptor inhibitor PARP enzymes and androgen receptor Not yet launched
Winlevi CLASCOTERONE Sun Pharma marketed Androgen Receptor Inhibitor [EPC] Androgen receptor 2020-01-01
Nubeqa darolutamide Bayer marketed androgen receptor (AR) 2019-01-01
Erleada apalutamide Johnson & Johnson marketed Androgen receptor 2018-01-01
APALUTAMIDE APALUTAMIDE marketed Androgen Receptor (AR) 2018-01-01
Aveed TESTOSTERONE UNDECANOATE Marius marketed Androgen Androgen receptor 2014-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Androgen receptor inhibitor class)

  1. Aragon Pharmaceuticals, Inc. · 1 drug in this class
  2. Arvinas Androgen Receptor, Inc. · 1 drug in this class
  3. Astellas Pharma · 1 drug in this class
  4. AstraZeneca · 1 drug in this class
  5. City of Hope Medical Center · 1 drug in this class
  6. Pfizer Inc. · 1 drug in this class
  7. Tata Memorial Centre · 1 drug in this class
  8. Triple Hair Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AZD8835 in combination with fulvestrant — Competitive Intelligence Brief. https://druglandscape.com/ci/azd8835-in-combination-with-fulvestrant. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: